Biomarin Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Biomarin Pharmaceutical
BMRN Stock  USD 68.81  2.36  3.32%   
Biomarin Pharmaceutical financial statements provide useful quarterly and yearly information to potential Biomarin Pharmaceutical investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Biomarin Pharmaceutical financial statements helps investors assess Biomarin Pharmaceutical's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Biomarin Pharmaceutical's valuation are summarized below:
Gross Profit
2.3 B
Profit Margin
0.1496
Market Capitalization
13.6 B
Enterprise Value Revenue
4.4123
Revenue
2.9 B
We have found one hundred twenty available fundamental signals for Biomarin Pharmaceutical, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Biomarin Pharmaceutical's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 27th of February 2025, Market Cap is likely to drop to about 8 B. In addition to that, Enterprise Value is likely to drop to about 9.8 B

Biomarin Pharmaceutical Total Revenue

3 Billion

Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 126 M, Selling General Administrative of 1.1 B or Total Revenue of 3 B, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.91. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Biomarin Pharmaceutical Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets7.3 B7 B4.3 B
Slightly volatile
Short and Long Term Debt Total578.2 M595.1 M773.8 M
Slightly volatile
Total Current Liabilities317.7 M607 M472.8 M
Slightly volatile
Total Stockholder Equity5.9 B5.7 B3 B
Slightly volatile
Property Plant And Equipment Net1.1 B1 B759.6 M
Slightly volatile
Accounts Payable160.3 M235.4 M249.5 M
Slightly volatile
Cash990 M942.8 M541.5 M
Slightly volatile
Non Current Assets Total3.9 B3.8 B2.4 B
Slightly volatile
Non Currrent Assets Other264 M251.4 M123.9 M
Slightly volatile
Cash And Short Term Investments619.4 M1.1 B825.2 M
Slightly volatile
Net Receivables693.6 M660.5 M319.3 M
Slightly volatile
Common Stock Shares Outstanding130.9 M196.7 M154.9 M
Slightly volatile
Liabilities And Stockholders Equity7.3 B7 B4.3 B
Slightly volatile
Non Current Liabilities Total594.3 M724 M765 M
Slightly volatile
Inventory1.3 B1.2 B558.6 M
Slightly volatile
Other Current Assets211.6 M201.5 M96.2 M
Slightly volatile
Other Stockholder Equity6.1 B5.8 B3.9 B
Slightly volatile
Total Liabilities912 M1.3 B1.2 B
Slightly volatile
Property Plant And Equipment Gross2 B1.9 B1 B
Slightly volatile
Total Current Assets3.4 B3.2 B1.8 B
Slightly volatile
Intangible Assets245.9 M255.3 M332.4 M
Slightly volatile
Common Stock Total Equity126.8 K211.6 K156.9 K
Slightly volatile
Short Term Investments274 M194.9 M326.4 M
Slightly volatile
Short Term Debt607 M578.1 M301.4 M
Pretty Stable
Common Stock133.2 K217.3 K158.1 K
Slightly volatile
Other Assets1.9 B1.8 B862 M
Slightly volatile
Long Term Debt557.4 M595.1 M651.4 M
Slightly volatile
Property Plant Equipment1.3 B1.3 B793.7 M
Slightly volatile
Other Liabilities81.8 M84.5 M101.7 M
Pretty Stable
Good Will124.9 M225.6 M148.6 M
Slightly volatile
Net Tangible Assets4.9 B4.7 B2.5 B
Slightly volatile
Long Term Debt Total730.7 M1.2 B756.3 M
Slightly volatile
Capital Surpluse3.7 B6 B3.8 B
Slightly volatile
Long Term Investments368 M521.2 M336.6 M
Slightly volatile
Non Current Liabilities Other123.8 M128.8 M113.2 M
Slightly volatile
Deferred Long Term Asset Charges309 M530.1 M354.5 M
Slightly volatile
Short and Long Term Debt339.2 M444.5 M484 M
Slightly volatile
Net Invested Capital5.5 B6.3 B4.6 B
Slightly volatile
Net Working Capital1.9 B2.6 B1.6 B
Slightly volatile
Capital Stock202.7 K191 K182.3 K
Slightly volatile
Capital Lease Obligations8 M7.6 M10.2 M
Slightly volatile

Biomarin Pharmaceutical Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative1.1 B1 B452.7 M
Slightly volatile
Total Revenue3 B2.9 B1.4 B
Slightly volatile
Gross Profit2.4 B2.3 B1.1 B
Slightly volatile
Other Operating Expenses2.5 B2.4 B1.5 B
Slightly volatile
Research Development784.5 M747.2 M553 M
Slightly volatile
Total Operating Expenses1.9 B1.8 B1.1 B
Slightly volatile
Non Recurring365.4 M689 M440 M
Slightly volatile
Interest Income78.6 M74.9 M32.7 M
Slightly volatile
Reconciled Depreciation110.3 M96.4 M95.5 M
Slightly volatile
Selling And Marketing Expenses480.5 M561.7 M426.5 M
Slightly volatile

Biomarin Pharmaceutical Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow792.9 M755.1 M475.6 M
Slightly volatile
Depreciation51.7 M88.1 M73.7 M
Slightly volatile
Capital Expenditures88.8 M85.4 M121.4 M
Pretty Stable
End Period Cash Flow990 M942.8 M541.5 M
Slightly volatile
Stock Based Compensation131.8 M202.5 M130.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.164.376625.3894
Slightly volatile
PTB Ratio3.912.20765.3563
Slightly volatile
Days Sales Outstanding96.3184.478889.4076
Slightly volatile
Book Value Per Share31.2629.774717.3223
Slightly volatile
Stock Based Compensation To Revenue0.110.0710.1027
Slightly volatile
Capex To Depreciation0.920.96981.9085
Slightly volatile
PB Ratio3.912.20765.3563
Slightly volatile
EV To Sales4.044.254825.0864
Slightly volatile
Sales General And Administrative To Revenue0.20.210.4742
Slightly volatile
Research And Ddevelopement To Revenue0.250.26180.9729
Slightly volatile
Capex To Revenue0.02840.02990.4429
Slightly volatile
Cash Per Share3.225.98714.889
Slightly volatile
Intangibles To Total Assets0.06140.06460.1388
Slightly volatile
Current Ratio6.835.32544.4196
Pretty Stable
Tangible Book Value Per Share28.7727.398814.4459
Slightly volatile
Receivables Turnover3.584.32064.363
Pretty Stable
Graham Number40.7338.792620.9924
Slightly volatile
Shareholders Equity Per Share31.2629.774717.3223
Slightly volatile
Debt To Equity0.170.10520.2784
Slightly volatile
Capex Per Share0.470.44950.7577
Pretty Stable
Revenue Per Share15.7715.01858.1513
Slightly volatile
Interest Debt Per Share2.853.06524.4457
Slightly volatile
Debt To Assets0.08090.08520.1795
Slightly volatile
Operating Cycle505860661
Slightly volatile
Price Book Value Ratio3.912.20765.3563
Slightly volatile
Ebt Per Ebit1.171.11891.2579
Very volatile
Company Equity Multiplier1.151.23521.4547
Slightly volatile
Long Term Debt To Capitalization0.09040.09520.1916
Slightly volatile
Total Debt To Capitalization0.09040.09520.2067
Slightly volatile
Debt Equity Ratio0.170.10520.2784
Slightly volatile
Quick Ratio6.043.29463.4319
Slightly volatile
Cash Ratio2.341.55331.5753
Slightly volatile
Cash Conversion Cycle903860553
Slightly volatile
Days Of Sales Outstanding96.3184.478889.4076
Slightly volatile
Price To Book Ratio3.912.20765.3563
Slightly volatile
Fixed Asset Turnover2.872.73611.7157
Slightly volatile
Debt Ratio0.08090.08520.1795
Slightly volatile
Price Sales Ratio4.164.376625.3894
Slightly volatile
Asset Turnover0.430.40830.3051
Slightly volatile
Gross Profit Margin1.010.79670.8561
Slightly volatile
Price Fair Value3.912.20765.3563
Slightly volatile

Biomarin Pharmaceutical Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8 B14.5 B13.1 B
Slightly volatile
Enterprise Value9.8 B15 B13.6 B
Slightly volatile

Biomarin Fundamental Market Drivers

Forward Price Earnings17.2117
Cash And Short Term Investments1.1 B

Biomarin Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Biomarin Pharmaceutical Financial Statements

Biomarin Pharmaceutical investors utilize fundamental indicators, such as revenue or net income, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue4.2 M4.4 M
Total Revenue2.9 B3 B
Cost Of Revenue580.2 M609.2 M
Stock Based Compensation To Revenue 0.07  0.11 
Sales General And Administrative To Revenue 0.21  0.20 
Research And Ddevelopement To Revenue 0.26  0.25 
Capex To Revenue 0.03  0.03 
Revenue Per Share 15.02  15.77 
Ebit Per Revenue 0.17  0.18 
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
How To Invest In Biomarin
Details
Is Biomarin Stock a good investment?
Details
What is Biomarin Pharmaceutical's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
6.449
Earnings Share
2.13
Revenue Per Share
15.018
Quarterly Revenue Growth
0.156
Return On Assets
0.0515
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY